{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-034185","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2026-07-22T12:35:29+00:00","discovered_at":"2026-07-22T12:40:00.355036+00:00","generated_at":"2026-07-22T12:40:07.207708+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kairos Pharma collaborates with Bayer to test ENV-105 + XOFIGO in mCRPC; market up to $1.3B","bullets":["Bayer to supply radium for Kairos' study of ENV-105 (carotuximab) with XOFIGO in metastatic castration-resistant prostate cancer.","Prior Phase 2 data showed 86% clinical benefit rate and median PFS >13 months in resistant mCRPC.","Addressable global market estimated at $570M–$1.3B.","ENV-105 targets CD105 to re-sensitize tumors; XOFIGO is FDA-approved alpha-emitting radiopharmaceutical.","Collaboration includes customary terms; Kairos responsible for study financing and management."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-034185","json":"https://secwatch.observer/filing/0001493152-26-034185.json","markdown":"https://secwatch.observer/filing/0001493152-26-034185.md","text":"https://secwatch.observer/filing/0001493152-26-034185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/0001493152-26-034185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T12:40:07.207708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}